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Background
Patients with juvenile idiopathic arthritis (JIA), non-
responsive to disease-modifying anti-rheumatic drugs
(DMARDs) are treated with anti-TNF agents. The aim of
this study was to evaluate the occurrence of adverse events
(AEs) in these refractory patients.
Patients and methods
In three tertiary centers patient charts were reviewed, and
for each anti-TNF drug the severity and type of AEs were
specified. Of 269 patients, 97% were on concomitant
DMARDs at anti-TNF onset. Their mean age was 5.4 years
(SD ± 3.8) at disease onset and 10.5 years (SD ± 3.9) at
anti-TNF onset.
Results
The total drug exposure was 665 years; etanercept expo-
sure was 354 years, infliximab 287, and adalimumab 24.
Of altogether 1057 AEs, 49 (5%) were considered as seri-
ous (Table 1). A total of 509 (49%) infections occurred, of
which 291 (57%) were upper respiratory tract infections.
Dermatological problems were documented in 57 (21%)
patients, and hypersensitivity reactions (consisting infu-
sion and injection site reactions) in 52 (19%). Neither
malignancies nor tuberculosis appeared, although one
patient had a mycobacterium avium pneumonia during
adalimumab therapy.
Conclusion
Infections were the most common AEs in patients with JIA
receiving anti-TNF therapy, but the rate of serious infec-
tions seemed to be low.
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Table 1: AEs and SAEs per patient-year during anti-TNF therapy
etanercept infliximab adalimumab all
AEs 1,40 1,51 2,34 1,48
SAEs 0,09 0,06 0,08 0,07
All infections 0,79 0,74 0,66 0,77
upper respiratory 0,47 0,40 0,33 0,44
serious infections 0,04 0,02 0,04 0,03
hypersensitivity reactions 0,03 0,23 0,29 0,12
